Fig. 3: Summarised clinical endpoints (objective response rate, durable clinical benefit rate, progression-free survival, overall survival).
From: A phase II trial of mTORC1/2 inhibition in STK11 deficient non small cell lung cancer
Forest plots indicating the median and 95% Credible Interval for (A) Objective Response rate, (B) Durable Clinical Benefit rate, (C) median Progression-free Survival time, and (D) median Overall Survival time. The vertical red lines for the co-primary outcomes of OR and DCB indicate the minimum clinically relevant threshold for the true rates that would generate a GO decision. Kaplan-Meier curves for (E) Progression-free Survival time, and (F) Overall Survival time.
